Uterine tumors with sarcomatous component: Past, present and future;Tumores uterinos con componente sarcomatoso. Pasado, presente y futuro

Oncologia

Volumn 29, Issue 7, 2006, Pages 11-16

  Rovirosa, Angels ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADENOCARCINOMA; CANCER INCIDENCE; CANCER SURGERY; CARCINOSARCOMA; CELL HETEROGENEITY; CHEMOTHERAPY; EDITORIAL; HISTOPATHOLOGY; HUMAN; MESENCHYME; METASTASIS; PROGNOSIS; UTERUS SARCOMA;

EID: 33750279078     PISSN: 03784835     EISSN: 03784835     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. WHO histological classification of tumours of the uterine corpus. In: Tavassoli FA & Devilee P. Pathology and Genetics of Tumours of breast and female genital organs. World health organizations classification of tumours. IARC Press, Lyon 2003. p 218.
2. Rovirosa A. Sarcomas Uterinos. En Cabero Ll, Iglesias X, Balagueró Ll, Xercavins J. Ginecología Oncológica. Guidotti Farma. Majadahonda (Madrid), 2005:161-170.
3. Amant F, Cadron I, Fuso L, Berteloot P, et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 2005; 98:274-280.
4. Achrya S, Hensley M, Montang A, Flemming G. Rare uterine cancers. The Lancet Oncol 2005; 6:961-971
5. Rovirosa A. Sarcomas Uterinos. Un reto para el oncólogo. Neoplasia 1995; 12(5):141-153.
6. Rovirosa A, Ascaso C, Ordi J, et al. Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with sarcomatous component? A retrospective study of prognostic factors on 60 patients stratified by stages. Int J Radiation Oncology Biol Phys 2002; 52(5): 1320-1329.
7. Guintoli RL, Metzinguer DS, Connie S et al. Retrospective review of 208 patients with leiomiosarcoma of the uterus: prognostic indicators, surgical management and adyuvant therapy. Gynecol Oncol 2003; 89:460-469.
8. Yamada SD, Burger RA, Brewster WR, Anton D, Kolher MF, Monk BJ. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients surgically evaluated carcinosarcoma of the uterus. Cancer 2000, 88:2782-2786.
9. Myerhofer K, Obermair A, Windbichler G et al. Leiomyoma of the uterus: a clinicopathologic multicenter study of 71 cases. Gynecol Oncol 1999; 74:196-201.
10. Rovirosa A, Ordi J, Ascaso C y cols. Factores pronósticos en los sarcomas uterinos: estudio retrospectivo de 21 años en el Hospital Clínico y Provincial de Barcelona. Med Clin (Barc) 1998; 111-172-176.
11. Omura GA, Blessing J, Major F et al. A randomized clinical trial of adjuvant adriamicin in uterine sarcomas: a gynecologic oncology group study. J Clin Oncol 1985; 3:1240-1245.
12. Tierney J. Adjuvant chemotherapy for localized respectable soft tissue sarcoma in adults, in the Cochrane database of systemic reviews. Oxford, the Cochrane library, 1999; vol 2:1-30.
13. Kanjeekal S, Chambers A, Fung Kee Fung M, Verma S. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol 2005; 97:624-637.